KunyongYang

Kunyong Yang's practice focuses on developing and managing global patent portfolios involving pharmaceutical, chemical, and biotechnology innovations, including small molecule drugs, lipid nanoparticles, antibody drug conjugates, radiopharmaceuticals, and chemical modification of oligonucleotides (e.g., siRNA, mRNA). He guides clients from the early stages of patent portfolio development, through the product development process, to the development of late-stage life cycle management strategies and regulatory extension opportunities. Particular small molecule pharmaceuticals that Kunyong has been involved with include REVLIMID^® (lenalidomide), ONUREG^® (azacitidine tablets), ALUNBRIG^® (brigatinib), iberdomide, mezigdomide, golcadomide, zidesamtinib, duvelisib, and eganelisib.

Kunyong also advises clients on due diligence matters, including providing patentability, validity, and freedom-to-operate analysis, in association with clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities. In addition, Kunyong has experience in Hatch-Waxman litigation and patent post-grant proceedings, including inter partes review (IPR) and post-grant review (PGR).

Representative clients include BMS/Celgene, AbbVie, Merck, Nuvalent, HUA Medicine, and Suzhou Abogen Biosciences Co.

Prior to joining Jones Day, Kunyong worked at the Genomics Institute of the Novartis Research Foundation as a medicinal chemist.